TY - JOUR
T1 - Alzheimer's Imaging Consortium
AU - Oyeniran, Olujide
AU - Donald, Kirsty
AU - Orunmuyi, Akintunde
AU - Karikari, Thomas K.
AU - Evans, Tavia E.
AU - Cakmak, Jasmine
AU - Draper, Ethan
AU - Ucheagwu, Valentine A.
AU - Hicks, Justin
AU - Rosa-Neto, Pedro
AU - Medina, Yasser Iturria
AU - Akinyemi, Rufus O.
AU - Ametamey, Simon Mensah
AU - Liu, Linshan
AU - Waa, Sheila
AU - Udeh-Momoh, Chi
AU - Okonkwo, Ozioma C.
AU - Anazodo, Udunna
N1 - Publisher Copyright:
© 2025 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2025/12
Y1 - 2025/12
N2 - BACKGROUND: In the next two decades, Africa is projected to have one of the highest number of people with Alzheimer's disease and related dementias (ADRD) (Figure 1). Neuroimaging tools, particularly magnetic resonance imaging (MRI) and positron emission tomography (PET), are established diagnostic tools for characterizing ADRD. However, the use of these tools is unevenly distributed globally and acutely lacking in Africa, particularly in Sub-Saharan Africa. Because ADRD prevalence and risk factors vary across populations and geospatial lines, there is a growing need to develop neuroimaging capacity for dementia research in diverse populations to expand our understanding of its characteristics. Here, we highlight gaps in dementia imaging research globally, identify associated barriers to their use in Africa, and provide a perspective on opportunities to enable dementia neuroimaging research across Africa. METHOD: We reviewed published data from literature and clinical trial databases for ongoing or past ADRD studies around the world with PET or MRI. We then estimated the number of sites, participants, and capacity (participants/site). We also used published data to estimate Africa's imaging infrastructure and personnel needs and costs. RESULT: A total of 49 countries (∼25% of all countries in the world) account for the global ADRD neuroimaging research (Figure 2). On a regional level, Africa has the least number of ADRD study sites and participants who have/will have PET or MRI (Figure 2). In Africa, only 4 countries have conducted ADRD research using MRI and none have published research or reported ongoing clinical trials using PET. The challenges with acquiring and operating neuroimaging infrastructure including high costs of scanner and radiotracer production as well as shortage of skilled personnel are fundamental barriers to dementia imaging research in Africa. At minimum, $29,321,441,393 is required to equip Africa with the neuroimaging infrastructure and personnel to bridge the gap (Figure 3).CONCLUSION:Thus, we propose, 1) increased imaging infrastructure investment, especially in low-cost technologies, 2) optimization of existing clinical imaging systems for advanced imaging, 3) collaborative training of local personnel through upskilling programs and 4) establishment of regional and global partnerships. Together these actions can transform dementia imaging capacity in Africa.
AB - BACKGROUND: In the next two decades, Africa is projected to have one of the highest number of people with Alzheimer's disease and related dementias (ADRD) (Figure 1). Neuroimaging tools, particularly magnetic resonance imaging (MRI) and positron emission tomography (PET), are established diagnostic tools for characterizing ADRD. However, the use of these tools is unevenly distributed globally and acutely lacking in Africa, particularly in Sub-Saharan Africa. Because ADRD prevalence and risk factors vary across populations and geospatial lines, there is a growing need to develop neuroimaging capacity for dementia research in diverse populations to expand our understanding of its characteristics. Here, we highlight gaps in dementia imaging research globally, identify associated barriers to their use in Africa, and provide a perspective on opportunities to enable dementia neuroimaging research across Africa. METHOD: We reviewed published data from literature and clinical trial databases for ongoing or past ADRD studies around the world with PET or MRI. We then estimated the number of sites, participants, and capacity (participants/site). We also used published data to estimate Africa's imaging infrastructure and personnel needs and costs. RESULT: A total of 49 countries (∼25% of all countries in the world) account for the global ADRD neuroimaging research (Figure 2). On a regional level, Africa has the least number of ADRD study sites and participants who have/will have PET or MRI (Figure 2). In Africa, only 4 countries have conducted ADRD research using MRI and none have published research or reported ongoing clinical trials using PET. The challenges with acquiring and operating neuroimaging infrastructure including high costs of scanner and radiotracer production as well as shortage of skilled personnel are fundamental barriers to dementia imaging research in Africa. At minimum, $29,321,441,393 is required to equip Africa with the neuroimaging infrastructure and personnel to bridge the gap (Figure 3).CONCLUSION:Thus, we propose, 1) increased imaging infrastructure investment, especially in low-cost technologies, 2) optimization of existing clinical imaging systems for advanced imaging, 3) collaborative training of local personnel through upskilling programs and 4) establishment of regional and global partnerships. Together these actions can transform dementia imaging capacity in Africa.
UR - https://www.scopus.com/pages/publications/105025740549
U2 - 10.1002/alz70862_110059
DO - 10.1002/alz70862_110059
M3 - Review article
C2 - 41433513
AN - SCOPUS:105025740549
SN - 1552-5260
VL - 21
JO - Alzheimer's & dementia : the journal of the Alzheimer's Association
JF - Alzheimer's & dementia : the journal of the Alzheimer's Association
M1 - e110059
ER -